M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors BioPharma DiveThe Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioPharma Dive The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. M&A / DealsOncologyRead full story Post navigation Previous: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersNext: Bayer wins MHRA approval for Kerendia in heart failure Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
